drugset / Trial / NCT00756262

Probiotic Lactobacillus GG to Eliminate VRE Colonization

NCT00756262

Phase 1 Terminated 11 enrolled Tufts Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The use of LGG will be associated with elimination of VRE colonization. The primary comparison will be VRE elimination rates among those patients that receive LGG compared to those that receive placebo. The primary endpoint will be the proportion of patients with VRE at one week after cessation of administration of study medication or placebo. The investigators assume that the placebo group will have very little spontaneous elimination of VRE and that the LGG group will be more likely to have eliminated VRE colonization at the end of one week.

Timeline

Start
2003-03
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lactobacillus rhamnosus GG Other / unclassified 1e+10 cells Oral

Indications

No indication recorded.